In recent years, it has been noted that the combination of radiation and immunotherapy is more benefitial than both modalities used separately. The interactions between immune checkpoint inhibitors and high-dose radiotherapy are curently an important topic of ongoing scientific trials. This review highlights some of the presented papers during the ESTRO 37 congress in 2018.
Rodolfo Chicas-Sett, Ignacio Morales-Orue, Delvys Rodriguez-Abreu, Pedro Lara-Jimenez. Clin Transl Radiat Oncol. 2018 Feb; 9: 5–11. 10.1016/j.ctro.2017.12.004
Sundahl N. et al. J Transl Med. 2017 Jun 29;15(1):150. doi: 10.1186/s12967-017-1251-3
Study of Pembrolizumab With or Without Platinum-based Combination Chemotherapy Versus Chemotherapy Alone in Urothelial Carcinoma (MK-3475-361/KEYNOTE-361) https://clinicaltrials.gov/ct2/show/NCT02853305
Xuanwei Zhang, MSc and Gabriele Niedermann, MD. Abscopal Effects With Hypofractionated Schedules Extending Into the Effector Phase of
the Tumor-Specific T-Cell Response. Int. Journal of Radiation Oncology
'End of an Era' for Chemo in Non-Small Cell Lung Cancer - Medscape - Jun 03, 2018.